Patients with HoFH have attenuated responsiveness to lipid lowering therapies such as statins, cholesterol absorption inhibition, and bile acid binding resins because of impaired LDL receptor expression [332]. The gene discussed is LDLR; the disease is homozygous familial hypercholesterolemia.